Standish M. Fleming is the Founding Managing Partner of Forward Ventures, a San Diego-based venture capital firm. See sector focus and contact routes.
Standish M. Fleming is the Founding Managing Partner of Forward Ventures, a San Diego-based venture capital firm, and a 30-year veteran who has helped raise and manage six venture funds totaling over $500 million. His investment thesis spans almost every segment of the healthcare industry, with a focus on therapeutics across Series A, B, and C stages. Fleming has led or participated in financings at all levels from pre-start-up to public company PIPEs, investing in both debt and equity. While specific check sizes are not publicly detailed, he is known to lead or participate significantly in rounds rather than merely follow. Notable portfolio companies include Triangle Pharmaceuticals (acquired by Gilead Sciences), Actigen (now part of Corixa/GlaxoSmithKline), Ciphergen Biosystems (now Vermillion, Inc.), and Ambit Biosciences (acquired by Daiichi Sankyo). Fleming served as the initial president and CEO of several of these ventures and was a founding board member of Arizeke Pharmaceuticals and Gryphon Therapeutics, reflecting his deep operational involvement. He is a past president of the Biotechnology Venture Investors Group and has helped start more than 15
Details on this investor come from filing and round data held in the StartupFundraising directory, refreshed on ingest. Founders use profiles like this one to qualify fit and to shortlist investors in San Diego.
Investors like Standish M. Fleming · Full investor directory · Investor access · Company funding database